Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldberg, M. A.
Right arrow Articles by Crandall, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldberg, M. A.
Right arrow Articles by Crandall, P. H.
NEUROLOGY 1978;28:881
© 1978 American Academy of Neurology

Human brain binding of phenytoin

Mark A. Goldberg, Ph.D., M.D. and Paul H. Crandall, M.D.

Departments of Neurology and Pharmacology, Harbor General Hospital Campus, and the Division of Neurosurgery, Center for the Health Sciences, University of California at Los Angeles.

Human brain tissue from nine patients (eight biopsy, one autopsy) was investigated for 3H-phenytoin-binding activity. Protein-related binding was determined by ultrafiltration and was found to resemble experimental animal tissue binding. Phenytoin binding was enhanced by prior lipid removal. Human brain lipid also interacted with 3H-phenytoin as measured by a partition coefficient technique employing hexane. Both human protein and lipid were quantitatively less active than in animals. Measurement of brain, serum, and CSF levels of phenytoin in six patients showed that brain levels were 4 to 10 times higher than free drug as measured in the CSF. It is concluded that under usual clinical circumstances, human brain accumulates phenytoin against a concentration gradient; the accumulative process may be due to binding of phenytoin to tissue proteins and phospholipids.

Reprint requests should be addressed to Dr. Mark A. Goldberg, Department of Neurology. Harbor General Hospital Campus, UCLA School of Medicine, 1000 West Carson Street, Torrance, CA 90509.

Presented in part at the twenty-ninth annual meeting of the American Academy of Neurology, April 1977, Atlanta. Georgia.

Accepted far publication May 15, 1978.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1978 by AAN Enterprises, Inc.